This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Obesity	Phosphoinositide 3-kinase (PI3K); PI3K α ; PI3K δ ; PTEN (MMAC1; TEP1)	Mouse studies suggest inhibiting PI3K could help treat obesity. In transgenic mice expressing about twice as much Pten (a Pi3k regulator) as wild-type mice, age-associated metabolic pathologies were decreased and energy expenditure was increased. In the Pten transgenic mice or in wild-type mice treated with the PI3Kα and PI3Kδ inhibitor CNIO-PI3Ki, brown adipose tissue activity, energy expenditure and lifespan were greater than those in untreated wild-type mice. Ongoing studies include testing the effect of PI3K inhibition in obese and lean mice. SciBX 5(13); doi:10.1038/scibx.2012.340 Published online March 29, 2012	Patent applications filed; available for licensing	Ortega-Molina, A. <i>et al. Cell Metab.</i>; published online March 6, 2012; doi:10.1016/j.cmet.2012.02.001 Contact: Manuel Serrano, Spanish National Cancer Research Center, Madrid, Spain e-mail: mserrano@cni.es